Last reviewed · How we verify
VKA-Based Regimen
VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation.
VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) prevention and treatment, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | VKA-Based Regimen |
|---|---|
| Also known as | Warfarin, Phenprogamma, Phenprocoumon, Previscan, Fluindione |
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Drug class | Vitamin K antagonist (VKA) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Vitamin K antagonists (VKAs) such as warfarin work by inhibiting the vitamin K-dependent gamma-carboxylation of clotting factors II, VII, IX, and X in the liver, thereby reducing their procoagulant activity. This anticoagulant effect is used to prevent and treat thromboembolic disorders. VKA-based regimens typically involve dose titration to achieve a target International Normalized Ratio (INR) for the specific clinical indication.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) prevention and treatment
- Mechanical heart valve thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Hepatotoxicity
- Drug-drug interactions
Key clinical trials
- A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) (PHASE2)
- Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF) (PHASE3)
- Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (PHASE3)
- Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VKA-Based Regimen CI brief — competitive landscape report
- VKA-Based Regimen updates RSS · CI watch RSS
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company portfolio CI